We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aptiv's (APTV) Q4 Earnings and Revenues Beat Estimates
Read MoreHide Full Article
Aptiv PLC (APTV - Free Report) reported fourth-quarter 2019 (ended Dec 31, 2019) earnings per share of $1.15 (on an adjusted basis), lower than the Zacks Consensus Estimate. Earnings decreased 19 cents year over year.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for Aptiv depicted a pessimistic picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for fourth-quarter 2019 earnings move down 1% over the last 60 days.
However, the company has an impressive earnings history having outperformed the Zacks Consensus Estimate in three of the last four quarters with an average beat of 8.4%.
Revenues Better Than Expected
Aptiv recorded total revenues of $3.6 billion which surpassed the Zacks Consensus Estimate of $3.5 billion. However, revenues compared unfavorably with the year-ago figure of $3.6 billion.
Key Stats to Note: For 2020, the company anticipates adjusted earnings to be in the range of $4.75-$5.05 per share. Net sales are expected between $14.5 billion and $14.9 billion.
Check back later for our full write up on this Aptiv earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Aptiv's (APTV) Q4 Earnings and Revenues Beat Estimates
Aptiv PLC (APTV - Free Report) reported fourth-quarter 2019 (ended Dec 31, 2019) earnings per share of $1.15 (on an adjusted basis), lower than the Zacks Consensus Estimate. Earnings decreased 19 cents year over year.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for Aptiv depicted a pessimistic picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for fourth-quarter 2019 earnings move down 1% over the last 60 days.
However, the company has an impressive earnings history having outperformed the Zacks Consensus Estimate in three of the last four quarters with an average beat of 8.4%.
Revenues Better Than Expected
Aptiv recorded total revenues of $3.6 billion which surpassed the Zacks Consensus Estimate of $3.5 billion. However, revenues compared unfavorably with the year-ago figure of $3.6 billion.
Aptiv PLC Price
Aptiv PLC price | Aptiv PLC Quote
Key Stats to Note: For 2020, the company anticipates adjusted earnings to be in the range of $4.75-$5.05 per share. Net sales are expected between $14.5 billion and $14.9 billion.
Zacks Rank: Currently, Aptiv has a Zacks Rank #3 (Hold) but that could change following the company’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this Aptiv earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>